Disease-Focused Discovery

PureTech established the underlying programs and platforms that resulted in 27 therapeutics and therapeutic candidates that are being advanced within PureTech's Wholly Owned Pipeline or by its Founded Entities, including two that have received both U.S. Food and Drug Administration (FDA) clearance and European marketing authorization.

View our corporate deck.

PureTech's Components of Value

Wholly Owned Pipeline

Our programs1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100-ILD
Deupirfenidone
Idiopathic pulmonary fibrosis (IPF)

2

IPF

~130K U.S.


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (IPF and Long COVID respiratory complications and related sequelae) and disorders of lymphatic flow, such as lymphedema. We are also exploring the potential evaluation of LYT-100 in radiation induced fibrosis, myocardial fibrosis and other organ system fibrosis.

LYT-100-COV
Deupirfenidone
Post-acute "Long" COVID2 with respiratory complications & related sequelae

2

Long COVID respiratory complications & related sequelae

>510M Worldwide


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (IPF and post-acute "Long" COVID with respiratory complications and related sequelae) and disorders of lymphatic flow, such as lymphedema. We are also exploring the potential evaluation of LYT-100 in radiation induced fibrosis, myocardial fibrosis and other organ system fibrosis.

LYT-100-LYMPH
Deupirfenidone
Lymphatic flow disorders, including lymphedema

2

Lymphatic flow disorders, including lymphedema

~1M U.S.


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (IPF and Long COVID respiratory complications and related sequelae) and disorders of lymphatic flow, such as lymphedema. We are also exploring the potential evaluation of LYT-100 in radiation induced fibrosis, myocardial fibrosis and other organ system fibrosis.

LYT-200
Anti-Galectin-9 MAb
Solid tumors

1

Solid tumors

>32K/year U.S. (Metastatic pancreatic cancer)
>33K/year U.S. (Metastatic CRC)
>4K/year U.S. (Metastatic cholangiocarcinoma)


Fully human monoclonal antibody designed to inhibit the activity of galectin-9, a key molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells, which we are developing for difficult-to-treat cancer indications with poor survival rates, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA).

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

>32K/year U.S. (Metastatic pancreatic cancer)
>33K/year U.S. (Metastatic CRC)
>4K/year U.S. (Metastatic cholangiocarcinoma)


Fully human IgG1 monoclonal antibody directed against the delta-1 chain of T cells bearing gamma delta-1 T cell receptors that we have designed to target and deplete immunosuppressive gamma delta-1 T cells in cancer.

LYT-300
Oral Allopregnanolone
Neurological and neuropsychological conditions

1

Neurological and neuropsychological conditions

Designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need. Allopregnanolone, a positive allosteric modulator of GABAA receptors, has therapeutic potential across a wide range of neurological conditions like depression, epilepsy and other neurological and neuropsychological conditions, but has poor oral bioavailability as a result of first-pass liver metabolism. An intravenous formulation of allopregnanolone is approved by the FDA as a 60-hour infusion for the treatment of post-partum depression, though the method of administration has limitations.

LYT-510
Oral Immunosuppressant
IBD/chronic pouchitis

Preclinical

Inflammatory bowel disease and chronic pouchitis

~3.9M U.S.


Oral inflammation-targeting formulation of tacrolimus, a potent immunosuppressant drug, in development for the potential treatment of inflammatory bowel disease (IBD) and chronic pouchitis. Tacrolimus is approved for certain indications, however its approval for IBD and chronic pouchitis has been hampered by systemic toxicities, narrow therapeutic window of activity and opportunistic infections that can arise from systemic immunosuppression. There is clinical data demonstrating that tacrolimus is effective in addressing IBD indications, but adverse events have held it back.

LYT-500
Oral IL-22 +
Immunosuppressant
IBD

Preclinical

Inflammatory bowel disease

~3.9M U.S.

Therapeutic candidate being advanced for the potential treatment of inflammatory bowel disease (IBD) that is designed with a dual mechanism of action to provide both mucosal repair and targeted resolution of tissue inflammation.
LYT-503/IMB-150
(Partnered program)
Non-opioid
IC/BPS

Preclinical

Interstitial cystitis/bladder pain syndrome

~4-12M U.S.


Therapeutic candidate being advanced as a partnered program for the potential treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) that is designed to selectively treat inflamed tissues along the bladder wall while minimizing the potential for drug-related side effects in healthy parts of the body.

Phase completedPhase in progressRegistration-enabling studies to begin in 1H2022

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.
2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS).

Founded Entities

$1.9B


Investments and Non-Dilutive Funding Raised by Founded Entities Since January 20173

Controlling Interest or Right to Receive Royalties

Advancing a novel category of treatments for weight management and gut related chronic diseases

23.5% Equity plus Royalties
COMMERCIAL
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
Plenity®4,5

Weight management

~150M U.S. (Overweight and obesity)

Commercial
Therapeutic Candidate:
Plenity®
For adolescents4

Adolescent weight management

~13.7M U.S.

Pending Discussion with FDA6
Therapeutic Candidate:
GS2004

Weight management in type 2 diabetes (T2D)/prediabetes

~32M U.S. (T2D)
~88M U.S. (Prediabetes)

Clinical Trial Complete
Therapeutic Candidate:
GS3004

Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease

~80-100M U.S.

Clinical
Therapeutic Candidate:
GS5004

Functional constipation

~35M U.S.

Pivotal

Advancing transformative medicines for people living with psychiatric and neurological conditions

5.6% Equity plus Royalties
PHASE 3
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
KarXT

Schizophrenia

~2.7M U.S.

Phase 3

Alzheimer’s disease psychosis

~3.2M U.S.

Phase 3 Ready

Building a regenerative biology platform for androgenetic alopecia, epithelial aging and other medical indications

76.0% Equity plus Royalties
PHASE 3 READY
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
FOL-004

Androgenetic alopecia

~90M U.S.

Phase 3 Ready

Pioneering a new category of oral therapies based on defined bacterial consortia

41.4% Equity
PHASE 3 READY
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
VE303

Clostridioides difficile

~100-120K/year U.S.

Phase 3 Ready
Therapeutic Candidate:
VE202

Inflammatory bowel disease

~3M U.S.

Phase 2 Ready
Therapeutic Candidate:
VE416

Food allergy

~2.5M U.S. (Peanut allergy)

Phase 1/2
Therapeutic Candidate:
VE800

Solid tumors

>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)

Phase 1
Therapeutic Candidate:
VE707
Gram-negative infections
Preclinical

Developing a voice-based technology platform to detect changes of health conditions

44.6% Equity
COMMERCIAL RELEASE
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
Sonde One for Respiratory4
Respiratory risk detection and monitoring app
Commercial Release
Therapeutic Candidate:
Sonde Mental Fitness4

Monitoring vocal features linked to depression, anxiety and cognition

~17M U.S.

Commercial Release

Engineering hydrogels to enable the oral administration of biologics

74.3% Equity
PRECLINICAL

Equity Interest Only

Pioneering the development of cognitive treatments through game-changing technologies

22.3% Equity
COMMERCIAL
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
EndeavorRx®7 (AKL-T01)8

ADHD

~6.4M U.S. (Pediatric ADHD)

Commercial
Therapeutic Candidate:
Cognitive dysfunction in depression

Major depressive disorder

Proof-of-concept completed
Therapeutic Candidate:
Cognitive dysfunction in multiple sclerosis

Multiple sclerosis

Proof-of-concept completed
Therapeutic Candidate:
Attention in autism spectrum disorder

Autism spectrum disorder

Proof-of-concept completed
Therapeutic Candidate:
Post-COVID cognitive dysfunction

Acute cognitive dysfunction

Early scientific and clinical research
Therapeutic Candidate:
Post-ICU cognitive dysfunction
Acute cognitive dysfunction
Early scientific and clinical research
Therapeutic Candidate:
Cancer-related cognitive impairment
Acute cognitive dysfunction
Early scientific and clinical research

Engineering hematopoietic stem cell therapies combined with targeted therapies

8.6% Equity
PHASE 1/2a
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
VOR33 (CD33)

Acute myeloid leukemia

~42,500/year U.S., Europe, Japan

Phase 1/2a
Myelodysplastic syndromes, myeloproliferative neoplasms
Preclinical
Therapeutic Candidate:
VCAR33
Bridge-to-transplant AML
Phase 1/2

Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of December 31, 2021, Controlled Founded Entities include Follica Incorporated, Vedanta Biosciences, Inc., Sonde Health, Inc. and Entrega, Inc., and Non-Controlled Founded Entities include Gelesis Holdings, Inc., Karuna Therapeutics, Inc., Akili Interactive Labs, Inc., Vor Bio Inc. Relevant ownership interests for Founded Entities were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2021, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Vor Bio, Karuna and Gelesis ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of March 4, 2022 and February 15, 2022 and March 31, 2022, respectively. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S. 
3 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations. Funding figure does not include Gelesis’ gross proceeds of approximately $105.0 million from its January 2022 SPAC merger.
4 These therapeutic candidates are regulated as devices and their development has been approximately equated to phases of clinical development.
5 Important Safety Information about Plenity®: Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity. To avoid impact on the absorption of medications: For all medications that should be taken with food, take them after starting a meal. For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician. The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor. Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.   
Contingent on FDA review of the research plan.
7 EndeavorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. There were no serious adverse events; 9.3% of subjects experienced side effects, including frustration, headache, dizziness, emotional reaction, nausea or aggression. EndeavorRx is only available to your patients through a prescription, and is not intended as a stand-alone therapeutic or a substitute for your patient’s medication.
8 Multiple IRBs have determined AKL-T01 to be a non-significant risk device. Akili has obtained IRB approval independently or in collaboration with independent clinical research institutions for all past and ongoing human data collection for clinical research in the United States. We do not control the clinical or regulatory development of Akili’s product candidates. We do not have a direct interest in Akili’s therapeutic or therapeutic candidates. Our interest in Akili’s therapeutic and therapeutic candidates is limited to our equity interest in Akili and any potential appreciation in the value of such equity interest, and we do not control the clinical or regulatory development of Akili’s therapeutic candidates. Akili is well-protected with a robust intellectual property portfolio. Akili was incorporated in February 2012.

Cash at Parent Level

$377.9M


PureTech Level Cash and Cash Equivalents as of March 31, 20229

9 This represents a non-IFRS measure used by management for planning and reporting purposes. Please see below for a reconciliation of this measure to consolidated cash and cash equivalents, which is the most directly comparable measure calculated in accordance with IFRS: 

PureTech Level Cash and Cash Equivalents is defined as cash and cash equivalents held at PureTech Health plc and its wholly-owned subsidiaries only. PureTech Level Cash and Cash Equivalents is an alternative performance measure which is adjusted and constitutes a non-IFRS measure. We believe that these non-IFRS performance measures, when provided in combination with IFRS measures, will provide investors, analysts and other stakeholders with helpful complementary information to better understand our financial position from period to period. The measures are not substitutable for IFRS measures and should not be considered superior to measures presented in accordance with IFRS. These figures are unaudited and do not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2021 or March 31, 2022.

Developing breakthrough medicines at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with leading pharma companies or their investment arms